Literature DB >> 22846739

Genetic testing by cancer site: endocrine system.

Robert Pilarski1, Rebecca Nagy.   

Abstract

Numerous hereditary syndromes, caused by mutations in multiple tumor suppressor genes and oncogenes, can cause tumors in organs of the endocrine system. The primary syndromes (and genes) addressed here include multiple endocrine neoplasia types 1 and 2 (MEN1 and RET genes), Cowden syndrome (PTEN), hereditary pheochromocytoma/paraganglioma syndromes (multiple genes), and von Hippel-Lindau disease (VHL). Clinical genetic testing is available for each of these syndromes and is generally directed to individuals with endocrine or other tumors and additional features suggestive of a hereditary syndrome. However, for some endocrine tumors, the proportion because of heredity is so high that genetic testing may be appropriate for all affected individuals. Management for hereditary cases typically involves aggressive screening and/or surgical protocols, starting at young ages to minimize morbidity and mortality. Endocrine tumors can be less commonly seen in a number of other hereditary syndromes (eg, neurofibromatosis), which are not reviewed in this section.

Entities:  

Mesh:

Year:  2012        PMID: 22846739     DOI: 10.1097/PPO.0b013e3182609458

Source DB:  PubMed          Journal:  Cancer J        ISSN: 1528-9117            Impact factor:   3.360


  3 in total

1.  Clinical utility gene card for: von Hippel-Lindau (VHL).

Authors:  Jochen Decker; Christine Neuhaus; Fiona Macdonald; Hiltrud Brauch; Eamonn R Maher
Journal:  Eur J Hum Genet       Date:  2013-08-28       Impact factor: 4.246

Review 2.  Sporadic multiple parathyroid gland disease--a consensus report of the European Society of Endocrine Surgeons (ESES).

Authors:  Marcin Barczyński; Robert Bränström; Gianlorenzo Dionigi; Radu Mihai
Journal:  Langenbecks Arch Surg       Date:  2015-11-05       Impact factor: 3.445

3.  Whole-exome sequencing identifies variants in invasive pituitary adenomas.

Authors:  Xiaolei Lan; Hua Gao; Fei Wang; Jie Feng; Jiwei Bai; Peng Zhao; Lei Cao; Songbai Gui; Lei Gong; Yazhuo Zhang
Journal:  Oncol Lett       Date:  2016-08-16       Impact factor: 2.967

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.